Philadelphia Eagles quarterback Jalen Hurts has been sidelined for the remainder of the season following a serious medical diagnosis that includes deep vein thrombosis and bilateral pulmonary embolism. The announcement was reported by ESPN’s Adam Schefter on October 19, revealing that Hurts’ condition was determined following a game played against the Jacksonville Jaguars in London on October 11. Initially managing what was believed to be a superficial blood clot, further examinations highlighted the much more severe presence of multiple blood clots in his lungs.
:max_bytes(150000):strip_icc():format(jpeg)/jalen-hurts-1-102026-577f6cedc130413ea471707dfdc92c39.jpg)
At the age of 28, Hurts’ diagnosis raises critical concerns from medical professionals regarding the nature and implications of his conditions. Dr. Jonathan Paul, a specialist in pulmonary embolism and head of the UChicago Medicine Pulmonary Embolism Response Team, emphasized the seriousness of deep vein thrombosis (DVT) and its potential consequences. DVT arises when a blood clot forms in a major vein, often in the legs, and it can lead to the development of dangerous pulmonary embolisms if the clot dislodges and travels to the lungs.
Dr. Paul elaborated on the potential causes of DVT, noting that trauma can trigger clot formation. In Hurts’ case, it is believed a cleat may have inadvertently injured a vein during play or practice, setting off the clotting process. The risks associated with DVT become significant if the clot disperses, leading to a pulmonary embolism—a condition noted by Dr. Paul as life-threatening, capable of obstructing blood flow from the heart and potentially causing cardiac arrest.
Symptoms of DVT can include leg pain and swelling, but it is the complications arising when the clot moves to the lungs that present grave risks. Medical professionals take DVT very seriously given the potentially life-threatening nature of pulmonary embolism. In Hurts’ situation, the diagnosis of multiple blood clots in both lungs added a severe dimension to his health challenge.
Standard treatment for DVT and pulmonary embolism typically involves anticoagulants, commonly referred to as blood thinners, which are administered for a minimum period of three months. Dr. Paul noted that, depending on follow-up assessments, some patients may require extended treatment if they remain at risk for further clotting. For Hurts, the implications of such treatment are profound, as it effectively prohibits him from engaging in physical activity, especially contact sports.
While on blood thinners, athletes like Hurts face a heightened risk of bleeding complications from even minor injuries. Dr. Paul cautioned that any substantial physical impact could lead to severe outcomes, such as significant internal bleeding—particularly in the case of head injuries, which could endanger life.
Following these developments, Nicole Lynn, Hurts’ agent, expressed an optimistic outlook regarding his health. She released a statement affirming that Hurts is “clinically stable” without significant functional impairments, and provided reassurance about his prognosis. Lynn indicated that a full recovery is expected, with a possible return to contact football activities once he is no longer on blood thinners.
Despite the disappointing news about his season, Hurts’ future seems to hold promise, provided he adheres to medical advice and prioritises his recovery. The focus now turns to supporting him through this challenging period, ensuring he regains both his physical health and his ability to return to the field in future seasons.
As Hurts navigates this unexpected journey, the importance of awareness regarding such health conditions is highlighted, especially in high-impact sports where the risk of injury is prevalent. The narrative of his recovery may also serve as a reminder of the human element behind professional athletics, where athletes are indeed vulnerable to serious health issues beyond the physical challenges of their sport.